Abstract
Cecal ligation and puncture (CLP) is one of the most widely utilized models for rat experimental polymicrobial sepsis. In this work, we examine how the anti-oxidant and anti-inflammatory drug Etanercept (ENT), which has been FDA-approved, might lessen the damaging effects of sepsis on renal tissues. In this study, rats were divided into four groups: the control group, which received just CLP; the solvent group, which received DMSO intravenously before CLP; and the treatment group, which received ENT intraperitoneally before CLP, might possibly reduce the risk of sepsis-induced renal tissue damage. According to our results, ENT reduced NF-kB, TNF-\(\alpha\), and TLR levels compared to the solvent alone group or control group. A positive tissue integrity was found in the ENT-pretreated group as compared to the solvent-only group or control group during a histopathological evaluation of the renal tissues. The findings indicate that ENT could potentially lower the risk of renal tissue damage due to CLP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
